Skip to main content

Advertisement

SpringerLink
Log in

Two-year visual outcome of polypoidal choroidal vasculopathy treated with photodynamic therapy combined with intravitreal injections of ranibizumab

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the 2-year outcomes of photodynamic therapy (PDT) combined with intravitreal injections of ranibizumab for polypoidal choroidal vasculopathy (PCV).

Methods

Ninety-five eyes with subfoveal PCV treated with combined therapy were followed for ≥24 months. The association between visual outcomes and single nucleotide polymorphisms in ARMS2 A69S and CFH I62V genes were examined without adjusting for multiple comparisons.

Results

Visual acuity (VA) improvement was observed at month 3 (P = 0.009). The improvement persisted until month 12 (P = 0.003), when VA began the decline back to baseline values at month 24. To investigate the factors associated with VA reduction during the second year, patients were divided into those with and those without a second-year VA reduction. Both patients with and without a second-year VA reduction showed similar VA changes over the first year. The first-year VA improvement was not predictive of the VA decline over the second year. Genetic analyses showed no significant difference in the frequency of the A risk allele of CFH I62V between patients with and without a second-year VA reduction. However, patients with the T risk allele of A69S had a higher rate of recurrence and were more likely to experience a reduction in VA during the second year when compared to patients without (P = 0.020 and P = 0.048, respectively).

Conclusions

PDT combined therapy resulted in significant visual recovery in the first year, which was not sustained during the second year. VA reduction in the second year was affected by genetic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic Polypoidal Choroidal Vasculopathy (IPCV). Retina 10:1–8

    Article  CAS  PubMed  Google Scholar 

  2. Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA (2010) Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 55:501–515

    Article  PubMed  Google Scholar 

  3. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y (2008) Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 92:70–73

    Article  CAS  PubMed  Google Scholar 

  4. Kokame GT, Yeung L, Lai JC (2010) Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 94:297–301

    Article  PubMed  Google Scholar 

  5. Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Ariga H (2012) One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 154:117–124

    Article  CAS  PubMed  Google Scholar 

  6. Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A, Yoshimura N (2010) Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol 54:310–319

    Article  CAS  PubMed  Google Scholar 

  7. Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A, Yoshimura N (2007) Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 144:7–14

    Article  CAS  PubMed  Google Scholar 

  8. Tano Y (2008) Guidelines for PDT in Japan. Ophthalmology 115:585–585

    Article  PubMed  Google Scholar 

  9. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y (2008) One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 115:141–146

    Article  PubMed  Google Scholar 

  10. Saito M, Iida T, Nagayama D (2008) Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 92:1642–1647

    Article  CAS  PubMed  Google Scholar 

  11. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32:1453–1464

    Article  CAS  PubMed  Google Scholar 

  12. Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP (2010) Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 150:666–673

    Article  CAS  PubMed  Google Scholar 

  13. Rouvas AA, Papakostas TD, Ntouraki A, Douvali M, Vergados I, Ladas ID (2011) Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina 31:464–474

    Article  CAS  PubMed  Google Scholar 

  14. Sato T, Kishi S, Matsumoto H, Mukai R (2010) Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol 149:947–954

    Article  CAS  PubMed  Google Scholar 

  15. Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M (2010) Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 150:48–54

    Article  CAS  PubMed  Google Scholar 

  16. Ruamviboonsuk P, Tadarati M, Vanichvaranont S, Hanutsaha P, Pokawattana N (2010) Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br J Ophthalmol 94:1045–1051

    Article  CAS  PubMed  Google Scholar 

  17. Lee YH, Lee EK, Shin KS, Lee KM, Kim JY (2011) Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy. Retina 31:1287–1293

    Article  CAS  PubMed  Google Scholar 

  18. Lai TY, Lee GK, Luk FO, Lam DS (2011) Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina 31:1581–1588

    Article  CAS  PubMed  Google Scholar 

  19. Saito M, Iida T, Kano M (2012) Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Retina 32:1272–1279

    CAS  PubMed  Google Scholar 

  20. Tomita K, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Otani A, Nakayama Y, Yoshimura N (2012) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol 153:68–80

    Article  CAS  PubMed  Google Scholar 

  21. Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M, Yoshimura N (2007) Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 27:335–341

    Article  PubMed  Google Scholar 

  22. Ojima Y, Tsujikawa A, Otani A, Hirami Y, Aikawa H, Yoshimura N (2006) Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy. Am J Ophthalmol 141:958–960

    Article  PubMed  Google Scholar 

  23. Akaza E, Mori R, Yuzawa M (2008) Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 28:717–722

    Article  PubMed  Google Scholar 

  24. Yamashiro K, Tsujikawa A, Nishida A, Mandai M, Kurimoto Y (2008) Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy. Jpn J Ophthalmol 52:457–462

    Article  PubMed  Google Scholar 

  25. Leal S, Silva R, Figueira J, Cachulo ML, Pires I, de Abreu JR, Cunha-Vaz JG (2010) Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up. Retina 30:1197–1205

    Article  PubMed  Google Scholar 

  26. Verteporfin Roundtable Participants (2005) Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25:119–134

    Article  Google Scholar 

  27. Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, Kita M, Nagai T, Fujihara M, Bessho N, Uenishi M, Kurimoto Y, Negi A (2013) Comparison of the effect of Ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol 156:644–651

    Article  CAS  PubMed  Google Scholar 

  28. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473–4480

    Article  PubMed  Google Scholar 

  29. Romano MR, Cipollone U, Semeraro F, Rinaldi M, Costagliola C (2010) Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up. Clin Ophthalmol 4:1237–1241

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Saito M, Iida T, Kano M, Itagaki K (2013) Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 251:2099–2110

    Article  CAS  PubMed  Google Scholar 

  31. Yoshida Y, Kohno T, Yamamoto M, Yoneda T, Iwami H, Shiraki K (2013) Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol 57:283–293

    Article  CAS  PubMed  Google Scholar 

  32. Kim M, Kim K, do Kim G, Yu SY, Kwak HW (2011) Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy. Ophthalmologica 226:205–213

    Article  CAS  PubMed  Google Scholar 

  33. Lee YA, Yang CH, Yang CM, Ho TC, Lin CP, Huang JS, Chen MS (2012) Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up. Am J Ophthalmol 154:872–880

    Article  CAS  PubMed  Google Scholar 

  34. Nemoto R, Miura M, Iwasaki T, Goto H (2012) Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Clin Ophthalmol 6:1633–1638

    CAS  PubMed Central  PubMed  Google Scholar 

  35. Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A, Yoshimura N (2008) Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 146:513–519

    Article  PubMed  Google Scholar 

  36. Kondo N, Honda S, Kuno S, Negi A (2009) Coding variant I62V in the complement factor H gene is strongly associated with polypoidal choroidal vasculopathy. Ophthalmology 116:304–310

    Article  PubMed  Google Scholar 

  37. Gotoh N, Nakanishi H, Hayashi H, Yamada R, Otani A, Tsujikawa A, Yamashiro K, Tamura H, Saito M, Saito K, Iida T, Matsuda F, Yoshimura N (2009) ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Am J Ophthalmol 147:1037–1041

    Article  CAS  PubMed  Google Scholar 

  38. Hayashi H, Yamashiro K, Gotoh N, Nakanishi H, Nakata I, Tsujikawa A, Otani A, Saito M, Iida T, Matsuo K, Tajima K, Yamada R, Yoshimura N (2010) CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 51:5914–5919

    Article  PubMed  Google Scholar 

  39. Chen H, Liu K, Chen LJ, Hou P, Chen W, Pang CP (2012) Genetic associations in polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Mol Vis 18:816–829

    PubMed Central  PubMed  Google Scholar 

  40. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF (2013) Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 120:593–599

    Article  PubMed Central  PubMed  Google Scholar 

  41. Bessho H, Honda S, Kondo N, Negi A (2011) The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Mol Vis 17:977–982

    CAS  PubMed Central  PubMed  Google Scholar 

  42. Sakurada Y, Kubota T, Imasawa M, Mabuchi F, Tanabe N, Iijima H (2010) Association of LOC387715 A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 30:1616–1621

    Article  PubMed  Google Scholar 

  43. Nakata I, Tsujikawa A, Yamashiro K, Otani A, Ooto S, Akagi-Kurashige Y, Ueda-Arakawa N, Iwama D, Yoshimura N (2013) Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 251:1073–1080

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported in part by a Grant-in-Aid for Scientific Research (24592625, 24249082) from the Japan Society for the Promotion of Science (JSPS), Tokyo, Japan.

The authors have full control of all primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data upon request.

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan

    Masayuki Hata, Akitaka Tsujikawa, Masahiro Miyake, Kenji Yamashiro, Sotaro Ooto, Akio Oishi, Isao Nakata, Ayako Takahashi & Nagahisa Yoshimura

Authors
  1. Masayuki Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akitaka Tsujikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahiro Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenji Yamashiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sotaro Ooto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akio Oishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Isao Nakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ayako Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nagahisa Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akitaka Tsujikawa.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hata, M., Tsujikawa, A., Miyake, M. et al. Two-year visual outcome of polypoidal choroidal vasculopathy treated with photodynamic therapy combined with intravitreal injections of ranibizumab. Graefes Arch Clin Exp Ophthalmol 253, 189–197 (2015). https://doi.org/10.1007/s00417-014-2675-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-014-2675-6

Keywords

Search

Navigation